Publication date: Mar 18, 2025
A novel self-amplifying mRNA (samRNA) amplification mechanism was first discovered in the SARS-CoV-2 replication-transcription system and named replicase cycling reaction (RCR). In principle, RCR is a replicase-mediated transcription reaction driven by the SARS-CoV-2 RNA-dependent RNA polymerases (RdRPs), which amplify a specific samRNA construct consisting of an RNA/mRNA sequence flanked by a 5′-end RdRP-reverse-promoter (5′-RdRP-RP) and a 3′-end RdRP-forward-promoter (3′-RdRP-FP) on both sides. Based on this samRNA composition, we had not only successfully established the first in-vitro RCR reaction for directly amplifying the SARS-CoV-2 genomic and subgenomic RNAs but also further used it in a combined in-vitro-transcription and RCR (IVT-RCR) protocol to identify new functions of the SARS-CoV-2 NSP7, NSP8, and NSP12 proteins, leading to a fast diagnostic assay for measuring the SARS-CoV-2 RdRP activity. These findings may shed a new light on the molecular mechanisms of SARS-CoV-2 replication and transcription. As a result, in addition to the previously found primer-dependent RNA synthesis activity of the coronaviral RdRP complexes, we herein reported another new 5’/3′-promoter-dependent, primer-independent samRNA synthesis mechanism mediated by the SARS-CoV-2 RdRP complex. Based on this novel RCR mechanism, the associated samRNA composition is conceivably useful for facilitating the design and development of next-generation RNA/mRNA medicines and vaccines.
Open Access PDF
Concepts | Keywords |
---|---|
Biochem | mRNA vaccine |
Fast | RNA medicine |
Mrna | SARS-CoV-2 |
Promoter | Self-amplifying mRNA (samRNA) |
Vaccines |
Semantics
Type | Source | Name |
---|---|---|
disease | IDO | replication |
disease | IDO | assay |
drug | DRUGBANK | Ademetionine |
drug | DRUGBANK | (S)-Des-Me-Ampa |
disease | MESH | COVID 19 pandemic |
disease | IDO | production |
disease | IDO | host |
disease | IDO | cell |
drug | DRUGBANK | Coenzyme M |
disease | IDO | protein |
disease | MESH | alveolar adenocarcinoma |
disease | IDO | reagent |
drug | DRUGBANK | Tretamine |
drug | DRUGBANK | Tromethamine |
drug | DRUGBANK | Spermidine |
disease | MESH | Vaccinia |
drug | DRUGBANK | Formaldehyde |
drug | DRUGBANK | 2′-Deoxycytidine 5′-triphosphate |
drug | DRUGBANK | Sodium lauryl sulfate |
disease | MESH | SSPE |
pathway | KEGG | Ribosome |
drug | DRUGBANK | Hyaluronic acid |
pathway | REACTOME | Digestion |
drug | DRUGBANK | Spinosad |
disease | MESH | infectious diseases |
disease | MESH | tumors |
disease | MESH | Ebola virus infection |
disease | MESH | Middle East respiratory syndrome |
drug | DRUGBANK | Carboxyamidotriazole |
pathway | KEGG | Virion |
drug | DRUGBANK | L-Leucine |